Guide for Combining Primary Tumors for Statistical Analysis in Rodent Carcinogenicity Studies

Author:

Keenan Charlotte1ORCID,Al-Haddawi Muthafar2,Bienvenu Jean-Guy3,Bradley Alys Elizabeth4ORCID,Brown Paul5ORCID,Chen Hepei5,Colman Karyn6ORCID,Elwell Michael7,Gatto Nicholas8ORCID,Goodman Dawn9,Jacob Binod8,Lanning Lynda5,McKinney LuAnn5,Muhlbradt Erin10,Perry Rick11,Piaia Alessandro12,Potenta Daniel13,Regan Karen S.14,Sefing Benjamin8,Thibodeau Michael15,Tibbs-Slone Erin16ORCID,Woicke Jochen17ORCID,Zwickl Craig M.18

Affiliation:

1. C.M. Keenan ToxPath Consulting, Doylestown, Pennsylvania, USA

2. Bristol Myers Squibb, New Brunswick, New Jersey, USA

3. Charles River Laboratories, Senneville, Quebec, Canada

4. Charles River Laboratories, Tranent, UK

5. U.S. Food & Drug Administration, Silver Spring, Maryland, USA

6. Novartis, Cambridge, Massachusetts, USA

7. Independent Consultant, Apex, North Carolina, USA

8. Merck & Co., Inc., Kenilworth, New Jersey, USA

9. Independent Consultant, Providence, Rhode Island, USA

10. Medical Science & Computing, Rockville, Maryland, USA

11. Pfizer, Groton, Connecticut, USA

12. Novartis, Basel, Switzerland

13. InStem, Winnabow, North Carolina, USA

14. Regan Path/Tox Services, Kewadin, Michigan, USA

15. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA

16. Charles River Laboratories, Mattawan, Michigan, USA

17. Independent Consultant, Scottsdale, Arizona, USA

18. Independent Consultant, Indianapolis, Indiana, USA

Abstract

The Tumor Combination Guide was created at the request of the U. S. Food and Drug Administration (FDA) by a Working Group of biopharmaceutical experts from international societies of toxicologic pathology, the Food and Drug Administration (FDA), and members of the Standard for Exchange of Nonclinical Data (SEND) initiative, to assist pharmacology/toxicology reviewers and biostatisticians in statistical analysis of nonclinical tumor data. The guide will also be useful to study and peer review pathologists in interpreting the tumor data. This guide provides a higher-level hierarchy of tumor types or categories correlating the tumor names from the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) publications with those available in the NEOPLASM controlled terminology (CT) code list in SEND. The version of CT used in a study should be referenced in the nonclinical study data reviewer’s guide (SDRG) (section 3.1) of electronic submissions to the FDA. The tumor combination guide instructions and examples are in a tabular format to make informed decisions for combining tumor data for statistical analysis. The strategy for combining tumor types for statistical analysis is based on scientific criteria gleaned from the current scientific literature; as SEND and INHAND terminology and information evolve, this guide will be updated.

Publisher

SAGE Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3